Evidence map›Paper›PMID 37156299›Full record

ArticleAmerican journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons2023

Clonal hematopoiesis of indeterminate potential and outcomes after heart transplantation: A multicenter study.

Kaushik Amancherla, Kelly H Schlendorf, Caitlyn Vlasschaert, Brandon D Lowery, Quinn S Wells, Sarah B See, Emmanuel Zorn, Paolo C Colombo, Muredach P Reilly, JoAnn Lindenfeld and 6 more

Open access · hybridAbstract readMulticenter Study
In one paragraph

Article in American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed, 1 pooled it
5.4field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 1 synthesis or guideline pooled it, 17 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Article
  4. Review
  5. Review
  6. Review
  7. Review
  8. Article
  9. Article
  10. Solid Organ Transplant Recipients Exhibit More TET2-Mutant Clonal Hematopoiesis of Indeterminate Potential Not Driven by Increased Transplantation Risk.Clinical cancer research : an official journal of the American Association for Cancer Research · 2024
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 4 institutions in 2 countries.

Kaushik AmancherlaDivision of Cardiovascular Medicine, Vanderbilt University Medical Center, Nashville, Tennessee, USA. Electronic address: kaushik.amancherla@vumc.org.
Kelly H SchlendorfDivision of Cardiovascular Medicine, Vanderbilt University Medical Center, Nashville, Tennessee, USA.
Caitlyn VlasschaertDepartment of Medicine, Queen's University, Kingston, Ontario, Canada.
Brandon D LoweryVanderbilt Institute for Clinical and Translational Research, Vanderbilt University Medical Center, Nashville, Tennessee, USA.
Quinn S WellsDivision of Cardiovascular Medicine, Vanderbilt University Medical Center, Nashville, Tennessee, USA; Department of Pharmacology, Vanderbilt University Medical Center, Nashville, Tennessee, USA.
Sarah B SeeColumbia Center for Translational Immunology, Columbia University Medical Center, New York City, New York City, USA.
Emmanuel ZornColumbia Center for Translational Immunology, Columbia University Medical Center, New York City, New York City, USA.
Paolo C ColomboDivision of Cardiology, Columbia University Medical Center, New York City, New York City, USA.
Muredach P ReillyDivision of Cardiology, Columbia University Medical Center, New York City, New York City, USA.
JoAnn LindenfeldDivision of Cardiovascular Medicine, Vanderbilt University Medical Center, Nashville, Tennessee, USA.
Nir UrielDivision of Cardiology, Columbia University Medical Center, New York City, New York City, USA.
Jane E FreedmanDivision of Cardiovascular Medicine, Vanderbilt University Medical Center, Nashville, Tennessee, USA.
Ravi V ShahDivision of Cardiovascular Medicine, Vanderbilt University Medical Center, Nashville, Tennessee, USA.
Javid MoslehiSection of Cardio-Oncology and Immunology, University of California San Francisco, San Francisco, California, USA.
Alexander G BickDivision of Genetic Medicine, Vanderbilt University Medical Center, Nashville, Tennessee, USA.
Kevin ClerkinDivision of Cardiology, Columbia University Medical Center, New York City, New York City, USA.
Vanderbilt University Medical Center · USColumbia University Irving Medical Center · USQueen's University · CAUniversity of California, San Francisco · US

Funding

Vanderbilt Institute for Clinical and Translational Research (VICTR) -Identifying correlates of functional immunity in SARS-CoV-2 convalescent plasmaUL1TR002243 · NCATS · VANDERBILT UNIVERSITY MEDICAL CENTER · PI Paul A. Harris, Wesley H Self · 2017 to 2026
$130.7M
VANDERBILT UNIVERSITY CTSA FOR PEDIATRIC RESEARCHUL1RR024975 · NCRR · VANDERBILT UNIVERSITY · PI BERNARD, GORDON RAPHAEL · 2007 to 2011
$45.7M
The Vanderbilt Institute for Clinical and Translational Research (VICTR)UL1TR000445 · NCATS · VANDERBILT UNIVERSITY MEDICAL CENTER · PI BERNARD, GORDON RAPHAEL · 2012 to 2016
$41.4M
Pharmacogenomics of Arrhythmia TherapyU19HL065962 · NHLBI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI RODEN, DAN M · 2010 to 2014
$17.4M
Understanding and preventing HLA-associated drug reactionsP50GM115305 · NIGMS · VANDERBILT UNIVERSITY MEDICAL CENTER · PI DENNY, JOSHUA C. · 2015 to 2019
$13.0M
The Genetic Epemiology of Multiple SclerosisR01NS032830 · NINDS · VANDERBILT UNIVERSITY · PI HAINES, JONATHAN L · 1995 to 2010
$8.9M
Epidemiologic Architecture for Genes Linked to Environment (EAGLE)U01HG004798 · NHGRI · VANDERBILT UNIVERSITY · PI CRAWFORD, DANA C · 2008 to 2013
$8.8M
VESPA: Vanderbilt Electronic Systems for Pharmacogenomic AssessmentRC2GM092618 · NIGMS · VANDERBILT UNIVERSITY · PI DENNY, JOSHUA C., RODEN, DAN M · 2009 to 2010
$6.4M
Immunologic and Antigenic Drivers of Immune Checkpoint Inhibitor-Associated MyocarditisR01HL156021 · NHLBI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI Justin M Balko, Javid J Moslehi · 2021 to 2026
$4.9M
Vanderbilt Genome Electronic Records ProjectU01HG006378 · NHGRI · VANDERBILT UNIVERSITY · PI RODEN, DAN M · 2011 to 2014
$4.0M
[18F]F-AraG as an imaging biomarker for early diagnosis and monitoring of cardiotoxicity related to doxorubicin and immune check point inhibitor therapyR01HL160688 · NHLBI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Jelena Levi, Youngho Seo · 2022 to 2026
$3.4M
Novel mechanisms and predictors of VEGF receptor inhibitor-associated hypertensionR01HL141466 · NHLBI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI MOSLEHI, JAVID J · 2019 to 2023
$3.3M
NCATS NIH HHS UL1 TR000445NCATS NIH HHS UL1 TR002243NCRR NIH HHS S10 RR025141NCRR NIH HHS UL1 RR024975NHGRI NIH HHS U01 HG004798NHGRI NIH HHS U01 HG006378NHLBI NIH HHS K23 HL148528NHLBI NIH HHS L30 HL165555NHLBI NIH HHS R01 HL141466NHLBI NIH HHS R01 HL155990NHLBI NIH HHS R01 HL156021NHLBI NIH HHS R01 HL160688NHLBI NIH HHS U19 HL065962NICHD NIH HHS R01 HD074711NIGMS NIH HHS P50 GM115305NIGMS NIH HHS RC2 GM092618NIH HHS DP5 OD029586NIH HHS S10 OD017985NIH HHS S10 OD025092NINDS NIH HHS R01 NS032830
6 · The paper itself

Abstract

Cardiac allograft vasculopathy (CAV) is a leading cause of late graft failure and mortality after heart transplantation (HT). Sharing some features with atherosclerosis, CAV results in diffuse narrowing of the epicardial coronaries and microvasculature, with consequent graft ischemia. Recently, clonal hematopoiesis of indeterminate potential (CHIP) has emerged as a risk factor for cardiovascular disease and mortality. We aimed to investigate the relationship between CHIP and posttransplant outcomes, including CAV. We analyzed 479 HT recipients with stored DNA samples at 2 high-volume transplant centers, Vanderbilt University Medical Center and Columbia University Irving Medical Center. We explored the association between the presence of CHIP mutations with CAV and mortality after HT. In this case-control analysis, carriers of CHIP mutations were not at increased risk of CAV or mortality after HT. In a large multicenter genomics study of the heart transplant population, the presence of CHIP mutations was not associated with an increased risk of CAV or posttransplant mortality.

Indexed as

Heart DiseasesHeart TransplantationVascular DiseasesAllograftsClonal HematopoiesisHumansRisk Factorscardiac allograft vasculopathyCHIPclonal hematopoiesis of indeterminate potentialheart transplanttransplant genomics

Identifiers

PMID37156299
PMCPMC10524751
OpenAlexW4372342401

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.